<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570582</url>
  </required_header>
  <id_info>
    <org_study_id>KGOG3017</org_study_id>
    <nct_id>NCT01570582</nct_id>
  </id_info>
  <brief_title>A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase II Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korean Gynecologic Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      purpose Primary endpoint

        -  To evaluate the 24 month disease free survival Second endpoints

        -  To evaluate the 24 month overall survival To analyze the toxicity and the quality of
           life
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 48 month from the date of IRB approval

      Patients enrolled in this study targets approximately 314 people. Completion of patient
      enrollment is expected to take approximately 24 month, approximately 24 month follow-up
      period is expected to be needed
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24month progression free survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity Profile</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>drug effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
Subjects assigned to Arm II Gemcitabine and Latin Neople every week based on the first day of the outpatient / inpatient treatment receive it. The subjects first received Gemcitabine given over 30 minutes followed by 30 minutes will be administered Neople Latin week.
Gemcitabine and eighth day of the foreign / hospitalization are given over 30 minutes.
Regimen of the progression of the disease, the subject can not continue to deny or toxic dose every 3 weeks until at least 6 cycles should be administered to. Subjects completed six cycles of medication which responds subjects, the researchers believe it is necessary to sustain if the regimen is</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin and paclitaxel</intervention_name>
    <description>Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.</description>
    <arm_group_label>drug effect</arm_group_label>
    <other_name>carboplatin , paclitaxel and Gemcitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with epithelial ovarian, fallopian tube cancer bokmakam or pathological
             diagnosis of recurrent states there must be must be present.

          -  Pathologically Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous
             adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed
             epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or
             adenocarcinoma not otherwise specified (NOS) have been diagnosed with possible
             participation.

          -  Patients with CA-125 (biochemical recurrence), as described below elevation or
             clinically measurable lesions or the measurement is not possible, as there should be
             evidence of recurrence.

          -  If at least one (record as the longest diameter) can be accurately measured in at
             least one lesion that is defined. For each lesion, such as MRI or CT, when measured by
             traditional methods should be at least 20mm spiral CT (spiral CT) have been measured
             to be less than 10mm when.

          -  Neutrophil (ANC) by 1500 / ㎣ more Platelet count 100,000 / ㎣ more Serum creatinine
             concentration 1.5mg/dL (133mol / l) or creatinine clearance less than 60ml/min should
             be at least two.

        Exclusion Criteria:

          -  Patients must be at least 18 years of age.

          -  Patients with epithelial ovarian, fallopian tube cancer bokmakam or pathological
             diagnosis of recurrent states there must be must be present.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea Institute of Radiological and Medical Sciences</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>April 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>April 3, 2012</last_update_submitted>
  <last_update_submitted_qc>April 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korean Gynecologic Oncology Group</investigator_affiliation>
    <investigator_full_name>Taek Sang Lee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent ovarian</keyword>
  <keyword>ECG</keyword>
  <keyword>GOG performance</keyword>
  <keyword>Hematologic g</keyword>
  <keyword>Blood chemistry and urinalysis h</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

